Douglas Arbetter - AstraZeneca | 人才画像

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 21 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety, Efficacy and Pharmacokinetics of AZD7442 (tixagevimab/cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

F. D. Richard Hobbs,Hugh Montgomery,Francisco Padilla,Jesus Abraham Simón-Campos,Douglas Arbetter,Seth Seegobin,Alexandre Kiazand,Katie Streicher,Nuria Martinez-Alier,Taylor S. Cohen,Mark T. Esser

INFECTIOUS DISEASES AND THERAPYno. 3 (2024): 521-533

引用0浏览0WOS引用

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

Gustavo H Kijak,Bahar Ahani,Douglas Arbetter, Fernando Chuecos,Vancheswaran Gopalakrishnan,Jagadish Beloor,Tyler Brady,Amy Nguyen,Tiffany L Roe,Nicolette Schuko,Tianhui Zhang,F D Richard Hobbs,Francisco Padilla,Elizabeth J Kelly,Hugh Montgomery,Katie Streicher

Infectious diseases and therapy（2023）

引用0浏览0WOS引用

Early Asthma Control Improvement with Benralizumab: 8-Week Interim Integrated Analysis from the Real-World XALOC-2 Study

Erika Penz,Thomas Rothe,Lieven Dupont,Tanja Plate,Sheena Kayaniyil, Peter Van Iperen, Isabelle Fovel,Vivian Shih,Trung Tran,Douglas Arbetter,David Cohen,Rohit Katial,Anat Shavit,Benjamin Emmanuel,Marek Lommatzsch

Pneumologie (2023)

引用0浏览0引用

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

F. D. Richard Hobbs,Hugh Montgomery,Francisco Padilla,Jesus Abraham Simón-Campos,Kenneth Kim,Douglas Arbetter,Kelly W. Padilla,Venkatesh Pilla Reddy,Seth Seegobin,Katie Streicher,Alison Templeton,Rolando M. Viani,Eva Johnsson,Gavin C. K. W. Koh,Mark T. Esser

Infectious diseases and therapyno. 9 (2023): 2269-2287

引用0浏览0WOS引用

Asthma Clinical Remission with Benralizumab in an Integrated Analysis of the Real-World XALOC-1 Study

D.A. Jackson,Girolamo Pelaia,Alicia Padilla,Michael S. Watt,Sheena Kayaniyil,Silvia Boarino, Jesus Sanchez Tena, Vivian E. Shih,Trung N. Tran,Douglas Arbetter,David J. Cohen,Rohit Katial,Justin Kwiatek,Anat Shavit,Benjamin Emmanuel,Parameswaran Nair

Journal of Allergy and Clinical Immunologyno. 2 (2023): AB13-AB13

引用0浏览0引用

529. Safety of AZD7442 (tixagevimab/cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

F D Richard Hobbs, H. E. Montgomery,Francisco Padilla,Jesus Abraham Simón Campos,Douglas Arbetter,Seth Seegobin,Alexandre Kiazand,Katie Streicher,Nuria Martinez-Alier,Taylor S. Cohen,Mark T. Esser

Open forum infectious diseasesno. Supplement_2 (2023)

引用0浏览0引用

1924. Outpatient Treatment with the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (tixagevimab/cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial

F D Richard Hobbs,Hugh Montgomery,Francisco Padilla,Kenneth Kim,Jesus Abraham Simón Campos,Douglas Arbetter,Kelly W Padilla,Venkatesh P Reddy,Seth Seegobin,Katie Streicher,Rolando M Viani,Gavin C KW Koh,Mark T Esser

Open forum infectious diseasesno. Supplement_2 (2022)

引用0浏览0引用

1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults

Gustavo H Kijak,Bahar Ahani,Douglas Arbetter,Tyler Brady, Fernando Chuecos,Vancheswaran Gopalakrishnan,Tiffany L Roe,Nicolette Schuko,F D Richard Hobbs,Francisco Padilla,Elizabeth J Kelly,Hugh Montgomery,Katie Streicher

Open Forum Infectious Diseasesno. Supplement_2 (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn